Michael Mutz

USPTO Granted Patents = 25 (Patent Applications = 11)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 70(Granted Patents)

Location History:

Freiburg i. Br., DE (2010 - 2014)
Freiburg, DE (2001 - 2015)
Lörrach, DE (2021)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2001-2021

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10919887 - Salts and solid forms of a monobactam antibiotic (2021-02-16),

2. 8946272 - Plymorphic forms of deferasirox (ICL670A) (2015-02-03),

3. 8846706 - Crystalline form K of imatinib mesylate (2014-09-30),

4. 8710216 - Organic compounds (2014-04-29),

5. 8680146 - Organic compounds (2014-03-25),

6. 8633213 - Crystalline form F of imatinib mesylate (2014-01-21),

7. 8592440 - Crystalline form I of imatinib mesylate (2013-11-26),

8. 8530522 - Organic compounds (2013-09-10),

9. 8513256 - Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (2013-08-20),

10. 8507515 - Crystalline form G of imatinib mesylate (2013-08-13),

11. 8487095 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2013-07-16),

12. 8436030 - Polymorphic forms of deferasirox (ICL670A) (2013-05-07),

13. 8349852 - Quinazolinone derivatives useful as vanilloid antagonists (2013-01-08),

14. 8198435 - Crystal form of N-benzoyl-staurosporine (2012-06-12),

15. 8198289 - Crystal form H imatinib mesylate for pharmaceutical use (2012-06-12),

Title: Innovations and Contributions of Michael Mutz in Pharmaceutical Patents

Introduction: Michael Mutz, based in Freiburg, Germany, is a distinguished inventor recognized for his significant contributions to the pharmaceutical industry. With an impressive portfolio of 25 patents, Mutz has played a pivotal role in advancing medical science through his innovative work on various compounds and formulations.

Latest Patents: Among Mutz's most notable patents is the invention related to “Salts and solid forms of a monobactam antibiotic.” This invention presents new solid forms, salts, and polymorphs of Compound X, a complex compound aimed at enhancing therapeutic efficacy through novel pharmaceutical compositions and manufacturing processes. Another key patent focuses on “Polymorphic forms of deferasirox (ICL670A),” which encompasses both crystalline and amorphous forms of a compound critical for treating health conditions. This patent details preparation processes and the application of the substance in developing medicaments for human treatment.

Career Highlights: Michael Mutz has had a remarkable career, with significant roles in major pharmaceutical companies such as Novartis AG and Novartis Pharma GmbH. His tenure at these prestigious institutions has allowed him to contribute to cutting-edge research and development, particularly in the field of drug formulation and patenting new medical innovations.

Collaborations: Throughout his career, Mutz has collaborated with esteemed professionals, including Hans Hofmann and Marion Mahnke. These partnerships have facilitated a fruitful exchange of ideas and expertise, fostering innovation in the pharmaceutical sector and contributing to the successful patenting of groundbreaking inventions.

Conclusion: Michael Mutz stands out as a prominent inventor in the pharmaceutical landscape, with 25 patents reflecting his dedication to improving healthcare through innovation. His notable work on new pharmaceutical forms and compounds not only enhances medical treatments but also exemplifies the impact of inventive collaboration in the scientific community.

This text is generated by artificial intelligence and may not be accurate.